comparemela.com
Home
Live Updates
CatalYm to Present Positive New Phase 2a Follow-up Data on G
CatalYm to Present Positive New Phase 2a Follow-up Data on G
CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
Related Keywords
Mccormick Place ,
Illinois ,
United States ,
Chicago ,
American ,
Phil Lhuilier ,
Ignacio Melero Bermejo ,
Catalym Gmb ,
Alison Opalko ,
Trophic Communications ,
Oncology Congress ,
American Society Of Clinical Oncology ,
Ted Human Effector Cell Relocation Phase ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Growth Differentiation ,
Presentation Details ,
Universidad De Navarra ,
Demand Mccormick Place ,
Ted Human Effector ,
Relocation Phase ,
Phill Huilier ,
Stephanie May ,
Ihr Portfolio ,